CYTOGENETIC STUDY OF TUBERCULOSIS PATIENTS BEFORE AND AFTER TUBERCULOSTATIC DRUG-TREATMENT


EKMEKCI A., SAYLI A.

MUTATION RESEARCH-ENVIRONMENTAL MUTAGENESIS AND RELATED SUBJECTS, vol.334, no.2, pp.175-183, 1995 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 334 Issue: 2
  • Publication Date: 1995
  • Doi Number: 10.1016/0165-1161(95)90009-8
  • Title of Journal : MUTATION RESEARCH-ENVIRONMENTAL MUTAGENESIS AND RELATED SUBJECTS
  • Page Numbers: pp.175-183

Abstract

Cytogenetic analyses were carried out in lymphocytes of 15 untreated tuberculosis (tb) patients and 15 other tb patients who had received combined tuberculostatic chemotherapy HRZ (isoniazid + rifampicin + pyrazinamide) for 2 months. The frequency of chromosomal aberrations and sister-chromatid exchanges (SCEs) did not show any statistically significant differences in the patients before treatment and after exposure to combined HRZ therapy as compared to controls (p > 0.05). However, we observed that the mitotic index was significantly decreased in both groups (p < 0.05). Based on the results of the present study, we believe there is no indication for a chromosome damaging effect of HRZ and their metabolites in human lymphocytes in vivo after treatment of tuberculosis patients with optimum doses.